Total | Patients starting with animated exercise program (Wii console)a1 | Patients starting with conventional home-based physical exercisesa1 | |
---|---|---|---|
Number of patients, n | 30 | 15 | 15 |
Age (years), mean (SD) | 56 (±9) | 52 (±8) | 59 (±9) |
Age (years), min. | 34 | 34 | 45 |
Age (years), max. | 69 | 65 | 69 |
Age > 60 years, n (%) | 11 (37 %) | 3 (20 %) | 8 (53 %) |
Age 50 – 60 years, n (%) | 10 (33 %) | 7 (47 %) | 3 (20 %) |
Age <50 years, n (%) | 9 (30 %) | 5 (33 %) | 4 (27 %) |
Female, n (%) | 25 (83 %) | 10 (67 %) | 15 (100 %) |
Disease duration (years), mean (SD) | 13 (±9) | 10 (±7) | 16 (±9) |
disease duration (years), max. | 36 | 26 | 36 |
disease duration (years), min. | 1 | 1 | 1 |
DAS28, mean (SD) | 2.8 (±1.2) | 3.0 (±1.5) | 2.6 (±0.9) |
DAS28 score, max. | 5.3 | 5.3 | 4.4 |
DAS28 score, min. | 0.5 | 0.9 | 0.5 |
HAQ-DI score, mean (SD) | 0.85 (±0.53) | 0.72 (±0.52) | 0.98 (±0.51) |
HAQ-DI score, max. | 1.75 | 1.75 | 1.63 |
HAQ-DI score, min. | 0.00 | 0.00 | 0.00 |
Patient’s VAS disease activity, mm | 17 | 16 | 18 |
Current biological DMARD therapy | |||
Rituximab, n (%) | 12 (40 %) | 7 (47 %) | 5 (33 %) |
Tocilizumab, n (%) | 10 (33 %) | 5 (33 %) | 5 (33 %) |
Abatacept, n (%) | 5 (17 %) | 2 (13 %) | 3 (20 %) |
Etanercept, n (%) | 2 (6 %) | 1 (7 %) | 1 (7 %) |
Certolizumab, n (%) | 1 (3 %) | 0 (0 %) | 1 (7 %) |
Previous biological DMARD therapy | |||
Rituximab, n (%) | 4 (13 %) | 2 (13 %) | 2 (13 %) |
Tocilizumab, n (%) | 3 (10 %) | 1 (7 %) | 2 (13 %) |
Abatacept, n (%) | 2 (6 %) | 1 (7 %) | 1 (7 %) |
Etanercept, n (%) | 10 (33 %) | 7 (47 %) | 3 (20 %) |
Certolizumab, n (%) | 1 (3 %) | 1 (7 %) | 0 (0 %) |
Golimumab, n (%) | 1 (3 %) | 0 (0 %) | 1 (7 %) |
Secukinumab, n (%) | 1 (3 %) | 1 (7 %) | 0 (0 %) |
Infliximab, n (%) | 6 (20 %) | 2 (13 %) | 4 (27 %) |
Anakinra, n (%) | 1 (3 %) | 1 (7 %) | 0 (0 %) |
≥ 3 previous biological DMARD’s, n | 7 (23 %) | 4 (27 %) | 3 (20 %) |
≥ 2 previous biological DMARD’s, n | 8 (27 %) | 4 (27 %) | 4 (27 %) |
only 1 previous biological DMARD, n | 6 (20 %) | 2 (13 %) | 4 (27 %) |